Key facts
- This page summarizes Tango Therapeutics, Inc.'s Form 4 filing for Blueprint Medicines Corp (BPMC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Dec 2021, 15:25.
Tango Therapeutics, Inc. - 08 Dec 2021 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)
- Reporting relationship
- Director
- Issuer ticker
- BPMC
- Reported as of
- 08 Dec 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Ariel Hurley, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Tango Therapeutics, Inc. filed Form 4 for Blueprint Medicines Corp (BPMC) on 10 Dec 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BPMC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +3,400
- Change %
- Price
- $0.000000
- Shares after
- 3,400
- Date
- 08 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BPMC
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +7,000
- Change %
- Price
- $0.000000
- Shares after
- 7,000
- Date
- 08 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,000
- Exercise price
- $98.72
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported transaction involved the Reporting Person's receipt of a grant of 3,400 restricted stock units in accordance with the Issuer's non-employee director compensation policy.
Footnote F2
This option vests with respect to 1/36th of the shares underlying the option on January 8, 2022 and as to an additional 1/36th of the shares underlying the option each month thereafter.